Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

It's possible that Alzheimer's disease could be added to the lengthening list of health conditions that can be improved by treatment with GLP-1 receptor agonists. The phase 2 ELAD study of Novo ...

Novo Nordisk has asked the FDA to block compounders from making versions of its older, once-daily GLP-1 agonist liraglutide. Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT ...